Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$0.37.
- Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) rose 6542.06% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year increase of 5314.14%. This contributed to the annual value of -$4.43 for FY2024, which is 73285.71% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.37 as of Q3 2025, which was up 6542.06% from -$0.46 recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $0.31 in Q2 2023 and a low of -$4.15 during Q4 2021
- In the last 5 years, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$0.77 in 2022 and averaged -$1.08.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 13333.33% in 2023, and later crashed by 885000.0% in 2024.
- Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$4.15 in 2021, then surged by 85.06% to -$0.62 in 2022, then soared by 111.29% to $0.07 in 2023, then crashed by 871.43% to -$0.54 in 2024, then soared by 31.48% to -$0.37 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.37 for Q3 2025, versus -$0.46 for Q2 2025 and -$0.42 for Q1 2025.